Ira Gantz
Overview
Explore the profile of Ira Gantz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A, et al.
Kidney Dis (Basel)
. 2025 Mar;
11(1):63-74.
PMID: 40028005
Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease. The aim...
2.
Raji A, Gantz I, Crutchlow M, Flynn H, Xu L, Rodgers A, et al.
Aliment Pharmacol Ther
. 2025 Feb;
61(7):1152-1162.
PMID: 39984821
Background: Fibroblast growth factor 21 (FGF21) is a metabolic regulator with demonstrated efficacy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). FGF21 signals through 'c' isoforms of the FGF receptors...
3.
Pandey A, Kolkailah A, McGuire D, Frederich R, Cater N, Cosentino F, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792342
Aims: In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic...
4.
Cosentino F, Dagogo-Jack S, Frederich R, Cannon C, Cherney D, Mancuso J, et al.
Diabetes Obes Metab
. 2024 Dec;
27(2):583-594.
PMID: 39696829
Aim: To assess weight loss and cardiorenal outcomes by baseline body mass index (BMI) in VERTIS CV. Methods: Patients with type 2 diabetes and atherosclerotic cardiovascular (CV) disease were randomized...
5.
Pandey A, Kolkailah A, Cosentino F, Cannon C, Frederich R, Cherney D, et al.
Eur Heart J
. 2023 Oct;
44(48):5163-5166.
PMID: 37864578
No abstract available.
6.
Dagogo-Jack S, Frederich R, Liu J, Cannon C, Shi H, Cherney D, et al.
J Clin Endocrinol Metab
. 2023 Jan;
108(8):2042-2051.
PMID: 36702781
Context: VERTIS CV evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Objective: The aim of these analyses was to assess the...
7.
Dagogo-Jack S, Cannon C, Cherney D, Cosentino F, Liu J, Pong A, et al.
Diabetes Obes Metab
. 2022 Mar;
24(7):1245-1254.
PMID: 35266296
Aim: To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose-lowering agent. Materials And Methods: VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin versus placebo,...
8.
Dagogo-Jack S, Pratley R, Cherney D, McGuire D, Cosentino F, Shih W, et al.
BMJ Open Diabetes Res Care
. 2021 Oct;
9(1).
PMID: 34620621
Introduction: Here we report the glycemic efficacy and safety of ertugliflozin in patients in the VERTIS CV cardiovascular outcome trial with chronic kidney disease (CKD) stage 3. Research Design And...
9.
Lingvay I, Greenberg M, Gallo S, Shi H, Liu J, Gantz I
Diabetes Obes Metab
. 2021 Mar;
23(7):1640-1651.
PMID: 33769675
Aim: To assess the efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) inadequately controlled by insulin. Materials And Methods:...
10.
Budoff M, Davis T, Palmer A, Frederich R, Lawrence D, Liu J, et al.
Diabetes Ther
. 2021 Mar;
12(5):1279-1297.
PMID: 33721213
Introduction: VERTIS CV is the cardiovascular outcome trial for the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin. A sub-study was conducted to assess the efficacy and safety of ertugliflozin in patients...